Guillain-Barré SyndromeNCT07907406
Comparison Between Efficacy of Gabapentin and Carbamazepine in Neuropathic Pain of Guillain-Barré Syndrome Patients
A study testing Gabapentin and Carbamazepine in people with Guillain-Barré Syndrome and Neuropathic Pain, run by Lahore General Hospital at 1 site in Pakistan.
Trial summary
This randomized controlled trial compared gabapentin with carbamazepine for the treatment of nerve-related pain in patients with Guillain-Barré syndrome who received plasma exchange. The study tested the hypothesis that pain scores after seven days of treatment differed between the two groups. Read more about this study
- Who is it for?
- Ages 16 to 65 years
- Conditions the study is for
- Guillain-Barré Syndrome, Neuropathic Pain
- What is being tested?
- Gabapentin and Carbamazepine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jan 2026to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients aged 16-65 years,
- Both genders,
- Diagnosed with GBS receiving plasma exchange.
Who cannot join
- Patients with considered to have a form of relapsing polyradiculoneuritis, poliomyelitis, pregnancy (on medical record).
- Renal failure patients (creatinine>1.88 mg/dl or on dialysis) or on a controlled sodium or potassium diet, already taking gabapentin or enrolled in another trial
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Lahore General Hospital, Lahore
Lahore, Punjab Province, 54000
About this study
This randomized controlled trial compared gabapentin with carbamazepine for the treatment of nerve-related pain in patients with Guillain-Barré syndrome who received plasma exchange. The study tested the hypothesis that pain scores after seven days of treatment differed between the two groups.
The study was conducted at Medical Unit III, Lahore General Hospital, Lahore, and included 60 patients of either sex aged 16-65 years. Patients were randomly assigned by a lottery method to two equal groups of 30 patients each. One group received gabapentin 300 mg three times daily, while the other received carbamazepine 100 mg three times daily. Both treatments were administered after plasma exchange, and patients were followed for seven days.
Pain severity was assessed using a numeric rating scale before treatment and after seven days. Mean pain scores after treatment were compared between the groups to assess their relative effectiveness. Age, sex, duration of Guillain-Barré syndrome, smoking, alcohol use, diabetes, and hypertension were recorded, and comparisons were also performed within subgroups defined by these characteristics.
- Conditions
- Guillain-Barré Syndrome, Neuropathic Pain
- Being tested
- Gabapentin, Carbamazepine
- Keywords
- Gabapentin, Carbamazepine, Guillain-Barré syndrome, Neuropathic pain, Plasma exchange, Pain management
- Medical subject headings
- Guillain-Barre Syndrome, Neuralgia, Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GabapentinDrug
Gabapentin 300 mg was administered three times daily for seven days to treat neuropathic pain.
CarbamazepineDrug
Carbamazepine 100 mg was administered three times daily to treat neuropathic pain, with pain assessment after seven days.
| Study group | Role | What they receive |
|---|---|---|
| Group A-Gabapentin | Experimental | Patients received gabapentin 300 mg three times daily for seven days after plasma exchange for Guillain-Barré syndrome. Receives: Drug: Gabapentin |
| Group B-Carbamazepine | Active comparator | Patients received carbamazepine 100 mg three times daily after plasma exchange Receives: Drug: Carbamazepine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean neuropathic pain score
Neuropathic pain severity was assessed using a numeric rating scale at baseline and after seven days of treatment. Mean pain scores at day seven were compared between patients receiving gabapentin and those receiving carbamazepine. Lower scores indicated less severe pain.
Measured: Baseline and 7 day after initiation of treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study start1 Jan 2026
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Guillain-Barré SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lahore General Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Muhammad Irfan Jamil, Lahore General Hospital
- Investigators
- Namra Nazir, Principal investigator, Lahore General Hospital, Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07907406
- Sponsor's protocol ID
- LahoreGeneralH23
- Status last verified
- Oct 2026
- First submitted
- 25 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Efficacy of Gabapentin and Carbamazepine in Neuropathic Pain of Guillain-Barré Syndrome Patients
- ClinicalTrials.gov ID
- NCT07907406
- Acronym / sponsor ID
- LahoreGeneralH23
- Conditions
- Guillain-Barré Syndrome, Neuropathic Pain
- Keywords
- Gabapentin, Carbamazepine, Guillain-Barré syndrome, Neuropathic pain, Plasma exchange, Pain management
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Lahore General HospitalOther government
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial compared gabapentin with carbamazepine for the treatment of nerve-related pain in patients with Guillain-Barré syndrome who received plasma exchange. The study tested the hypothesis that pain scores after seven days of treatment differed between the two groups.
The study was conducted at Medical Unit III, Lahore General Hospital, Lahore, and included 60 patients of either sex aged 16-65 years. Patients were randomly assigned by a lottery method to two equal groups of 30 patients each. One group received gabapentin 300 mg three times daily, while the other received carbamazepine 100 mg three times daily. Both treatments were administered after plasma exchange, and patients were followed for seven days.
Pain severity was assessed using a numeric rating scale before treatment and after seven days. Mean pain scores after treatment were compared between the groups to assess their relative effectiveness. Age, sex, duration of Guillain-Barré syndrome, smoking, alcohol use, diabetes, and hypertension were recorded, and comparisons were also performed within subgroups defined by these characteristics.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A-Gabapentin | Experimental | Drug: GabapentinPatients received gabapentin 300 mg three times daily for seven days after plasma exchange for Guillain-Barré syndrome. |
| Group B-Carbamazepine | Active comparator | Drug: CarbamazepinePatients received carbamazepine 100 mg three times daily after plasma exchange |
Who may qualify
- Ages
- 16 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Patients aged 16-65 years,
- Both genders,
- Diagnosed with GBS receiving plasma exchange.
Key exclusion criteria (2 listed)
- Patients with considered to have a form of relapsing polyradiculoneuritis, poliomyelitis, pregnancy (on medical record).
- Renal failure patients (creatinine>1.88 mg/dl or on dialysis) or on a controlled sodium or potassium diet, already taking gabapentin or enrolled in another trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GabapentinGabapentin 300 mg was administered three times daily for seven days to treat neuropathic pain. | Drug | Group A-Gabapentin |
| CarbamazepineCarbamazepine 100 mg was administered three times daily to treat neuropathic pain, with pain assessment after seven days. | Drug | Group B-Carbamazepine |
Primary outcome
Mean neuropathic pain score
Time frame: Baseline and 7 day after initiation of treatment.
Neuropathic pain severity was assessed using a numeric rating scale at baseline and after seven days of treatment. Mean pain scores at day seven were compared between patients receiving gabapentin and those receiving carbamazepine. Lower scores indicated less severe pain.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
Related trials for Guillain-Barré Syndrome
Recruiting
High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND Project
Critical Illness Myopathy, Guillain Barré Syndrome
Not yet recruitingPhase 2
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS)
RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Guillain-Barre Syndrome
Not yet recruitingObservational study
Peripheral Nerve Ultrasound in Children With Guillain-Barré Syndrome
Guillain-Barre Syndrome
Not yet recruitingObservational study
Myocardial Changes in Pediatric Guillain-Barré Syndrome
Myocardial Dysfunction, Guillain-Barre Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Namra Nazir principal investigator
Lahore General Hospital, Lahore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Gabapentin and Carbamazepine in people with Guillain-Barré Syndrome and Neuropathic Pain, run by Lahore General Hospital at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean neuropathic pain score (time frame: Baseline and 7 day after initiation of treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.